Following the team of Chen Wei, another new crown vaccine in China will enter clinical trials: inactivated vaccine
Reporter Xue Shasha
Another new Chinese pneumonia vaccine will enter clinical trials.
On April 13th, Peng Mei News (www.thepaper.cn) noticed that the new coronavirus (COVID-19) inactivated vaccine (Vero cells) Ⅰ / Ⅱ developed by Sinopharm Group Wuhan Biological Products Research Institute Co., Ltd. The Phase III clinical trial is in the pre-registration state of “passed review” in the China Clinical Trial Registration Center.
According to public information, this is the second new coronavirus vaccine registered in clinical trials in China after the team of Chen Wei, academician of the Chinese Academy of Engineering and researcher of the Academy of Military Medical Sciences, Academy of Military Sciences.
With the severe situation of the international epidemic situation, the development of new coronavirus vaccines has become increasingly urgent. According to the previous press conference of the Joint Defense and Control Mechanism of the State Council of China, after the outbreak, China chose five technical routes to accelerate the development of new coronavirus vaccines, including inactivated vaccines, genetically engineered recombinant subunit vaccines, adenovirus vector vaccines, and attenuation Influenza virus vector vaccine and nucleic acid vaccine. It can be seen that the five technical routes adopted by China cover the major types of new coronavirus vaccines under study worldwide.
The clinical trial registration information shows that the research and development registration title of the Wuhan Institute of Biological Products Co., Ltd. is "New Coronavirus (COVID-19) Inactivated Vaccine (Vero Cell) Randomized, Double-blind, Placebo Parallel Control Phase I / II Clinical "Trial"; the official scientific name of the research topic is: Randomized, double-blind placebo parallel control I / II to evaluate the safety and immunogenicity of the new coronavirus inactivated vaccine (Vero cells) in healthy people aged 6 years and above Phase clinical trials.
At present, the clinical study has been approved by the ethics committee and is in the pre-registration state of "passed review".
"China Biotech has achieved important stage results in the research and development of the new inactivated vaccine, and is expected to provide a" killer "for winning the decisive battle against the epidemic." At the press conference held by the State Council's joint defense and control mechanism on the afternoon of April 8, Sinopharm Group Chairman Liu Jingzhen said.
According to Peng Mei News reported on April 12, Academician Zhong Nanshan once said in a meeting with South Korean epidemic prevention experts that now five vaccines in China are being developed at the same time, and adenovirus vector vaccines and fully inactivated vaccines are currently being carried out faster. The first phase of clinical trials of adenovirus vaccines has begun, and clinical trials of fully inactivated vaccines will soon begin. "We need to observe for a period of time after the clinical trial, usually one to two years, but it may also be listed in advance due to the development of the disease."
On the evening of the previous day, on the evening of the 11th, organized by the People's Daily and other media, "New Coronary Pneumonia Anti-epidemic Cloud Seminar", Chairman of China Biotechnology Yang Xiaoming introduced that among the five technologies for the development of new coronary pneumonia vaccines in China, the progress of inactivated vaccine Faster and more mature technology, "I believe that the domestic new crown vaccine will meet you soon."
According to previous statistics of the World Health Organization (WHO), as of March 21, there are 51 candidate vaccines in the world in development, and two of them have entered the clinical trial stage. One is the American biotechnology company Moderna announced on March 16 local time that the mRNA vaccine developed by the company began human trials.
The other is that the scientific research team led by Chen Wei, academician of the Chinese Academy of Engineering and researcher of the Academy of Military Medical Sciences, using the adenovirus vector, developed a recombinant new coronavirus (2019-COV) vaccine that passed the clinical research registration review on March 16. Evaluation; at 20:18 on the same day, approved to enter the clinical trial. As of now, the team of Chen Wei is recruiting volunteers for Phase II clinical trials for clinical trials.
That is to say, the inactivated new coronavirus (COVID-19) vaccine developed by Sinopharm Group China Wuhan Bioproducts Research Institute Co., Ltd. may be the third new coronavirus vaccine in clinical trials in the world.
So how long will it take to develop an approved new coronavirus vaccine that can be used on a large scale? The Director General of the World Health Organization Tan Desai said at a regular press conference that the development of the new crown vaccine will take at least 12 to 18 months. Anthony Fudge, director of the National Institute of Allergy and Infectious Diseases, has previously stated that even if the initial safety test of the vaccine is going well, it will take a year to a year and a half from its large-scale application.